Elevated expression of MCL-1 has been observed in CML and AML patients and associated with poor clinical outcome and chemoresistance in leukemia cells [37, 38]. This evidence concerns the gene MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive.